Loading...
•
Mar 31, 2024
Recursion Pharmaceuticals Q1 2024 Earnings Report
Recursion Pharmaceuticals reported its Q1 2024 financial results and provided business updates.
Key Takeaways
Recursion Pharmaceuticals reported a revenue of $13.8 million and a net loss of $91.4 million for the first quarter of 2024. The company is on track to read out multiple Phase 2 clinical trials in the coming quarters and has completed performance benchmarking on its next-generation supercomputer, BioHive-2.
On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024.
Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer.
Transcriptomics technology has continued to be scaled to more than 1 million transcriptomes.
Entered into a multi-year agreement with Helix to access hundreds of thousands of de-identified records.
Recursion Pharmaceuticals
Recursion Pharmaceuticals
Recursion Pharmaceuticals Revenue by Segment
Revenue by Segment
Collaborative agreements Revenue
CapyFin.com